SMAD4 loss is associated with cetuximab resistance and induction of MAPK/JNK activation in…
Credit: Insilico Medicine Summary: Cetuximab, an anti-EGFR monoclonal antibody and the only FDA-approved targeted therapy against advanced head and neck squamous cell carcinoma (HNSCC), has...













